Eli Lilly (LLY) Is Up 6.0% After Obesity Drug Data And $4.5B Manufacturing Push - Has The Bull Case Changed?

Earlier this week, Eli Lilly reported detailed late-phase obesity trial results showing long-term weight maintenance with injectable Zepbound and oral Foundayo, while also committing an additional US$4.50 billion to expand Indiana manufacturing for its incretin and genetic medicine portfolio.
The combination of durable weight-loss data and large-scale production build-out underscores how central obesity and metabolic drugs have become to Lilly’s broader pharmaceutical strategy.
We’ll now...